Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04687020 · ClinicalTrials.gov registry record · Phase 4
Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)
A Phase 4 study of Duchenne Muscular Dystrophy, sponsored by NS Pharma.
- Active
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
- 5
- Study locations
NCT04687020: Active Phase 4 study of Duchenne Muscular Dystrophy, sponsored by NS Pharma.
NCT04687020 is a Phase 4 study of Duchenne Muscular Dystrophy that is active but no longer recruiting, run by NS Pharma. The registered enrollment target is 9 participants, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04687020, a Phase 4 study of Duchenne Muscular Dystrophy, is active but no longer recruiting, sponsored by NS Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
- 5
- Study locations
Study Summary
The VILT-502 study is Non-interventional Study(United States)/Low-intervention Clinical Trial (Canada) of Viltolarsen administered intravenously once weekly for 10 years to boys with DMD who complete the NS-065/NCNP-01-202 study.
Conditions Studied
Interventions
- DRUG Viltolarsen
Study Locations (5)
California
- UC Davis - Sacramento
Illinois
- Lurie Children's Hospital - Chicago
North Carolina
- Duke University Medical Center - Durham
Virginia
- Children's Hospital of Richmond at VCU - Richmond
Alberta
- Alberta Children's Hospital - Calgary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-06-10 |
| Est. Completion | 2032-10 |
| Phase | Phase 4 |
What the registry record for NCT04687020 still lists
NCT04687020 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which Viltolarsen is the first listed.
NCT04687020 lists 5 locations in 5 states (California, Illinois, North Carolina).
Frequently Asked Questions
What is clinical trial NCT04687020 about?
NCT04687020 is a clinical study titled "Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)". The VILT-502 study is Non-interventional Study(United States)/Low-intervention Clinical Trial (Canada) of Viltolarsen administered intravenously once weekly for 10 years to boys with DMD who complete the NS-065/NCNP-01-202 study.
What is the current status of trial NCT04687020?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2021-06-10. Estimated completion is 2032-10.
What conditions does trial NCT04687020 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy.
What interventions are being tested in trial NCT04687020?
The interventions under investigation include: Viltolarsen (DRUG).
Who is sponsoring clinical trial NCT04687020?
This trial is sponsored by NS Pharma, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04687020 being conducted?
This trial has 5 study locations across California, Illinois, North Carolina, Virginia, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04687020's enrollment target sits among peer trials
9 44th of 48 higher than 5 of 48 other Duchenne Muscular Dystrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Duchenne Muscular Dystrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Once Weekly Infant Corticosteroid Trial for DMD
RECRUITING · Phase 4
-
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
RECRUITING · Phase 1
-
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
RECRUITING · Phase 2
-
The Duchenne Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI